BIRB 796 has Distinctive Anti-inflammatory Effects on Different Cell Types.
- Author:
Soyoon RYOO
1
;
Jida CHOI
;
Jaemyung KIM
;
Suyoung BAE
;
Jaewoo HONG
;
Seunghyun JO
;
Soohyun KIM
;
Youngmin LEE
Author Information
- Publication Type:Original Article
- Keywords: p38MAPK; BIRB 796; Inflammatory cytokine; Inflammatory signal pathways; LPS
- MeSH: Blotting, Western; Cytokines; Interleukin-8; Interleukins; Phosphorylation; Protein Kinases; Signal Transduction; Tumor Necrosis Factor-alpha
- From:Immune Network 2013;13(6):283-288
- CountryRepublic of Korea
- Language:English
- Abstract: The pro-inflammatory cytokines tumor necrosis factor-alpha (TNFalpha) and interleukin (IL)-1beta are crucial mediators involved in chronic inflammatory diseases. Inflammatory signal pathways regulate inflammatory cytokine expression-mediated by p38 mitogen activated protein kinase (p38MAPK). Therefore, considerable attention has been given to p38MAPK as a target molecule for the development of a novel anti-inflammatory therapeutics. BIRB 796, one of p38MAPK inhibitor, is a candidate of therapeutic drug for chronic inflammatory diseases. In this study, we investigated the effect of BIRB 796 on inflammatory cytokine productions by lipopolysaccharide (LPS) in different immune cell types. BIRB 796 reduced LPS-mediated IL-8 production in THP-1 cells but not in Raw 264.7 cells. Further analysis of signal molecules by western blot revealed that BIRB 796 sufficiently suppressed LPS-mediated phosphorylation of p38MAPK in both cell types whereas it failed to block inhibitor of kappa B (I-kappaB) degradation in Raw 264.7 cells. Taken together, these results suggest that the anti-inflammatory function of BIRB 796 depends on cell types.
